瑞波西利联合内分泌治疗用于绝经前侵袭性HR+/HER2-晚期乳腺癌患者:随机Ⅱ期RIGHT Choice试验

Randomized PhaseⅡRIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2-Advanced Breast Cancer Treated With Ribociclib and Endocrine Therapy

下载PDF

导出

摘要 1文献来源Lu Y-S, Mahidin EIBM, Azim H, et al.Abstract GS1-10:Primary results from the randomized phaseⅡRIGHT Choice trial of premenopausal patients with aggressive HR+/HER2-advanced breast cancer treated with ribociclib+endocrine therapy vs physician’s choice combination chemotherapy[J].Cancer Res,2023,83(5S):GS1-10.

作者徐菲李培勇 XU Fei;LI Pei-yong(Department of Oncology,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center,Guangzhou 510060,China;不详)

机构地区中山大学肿瘤防治中心内科南方医科大学附属广东省人民医院(广东省医学科学院)乳腺肿瘤科

出处《循证医学》 2023年第2期92-95,共4页 The Journal of Evidence-Based Medicine

关键词 RIGHT Choice试验瑞波西利内分泌治疗联合化疗晚期乳腺癌 RIGHT Choice trial ribociclib endocrine therapy combination chemotherapy advanced breast cancer

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献2

1国家肿瘤质控中心乳腺癌专家委员会,中国抗癌协会乳腺癌专业委员会,中国抗癌协会肿瘤药物临床研究专业委员会,徐兵河,马飞,樊英,李逸群.中国晚期乳腺癌规范诊疗指南(2022版)[J].中华肿瘤杂志,2022,44(12):1262-1287. 被引量：148
2Rong Guo,Jing Si,Jingyan Xue,Yonghui Su,Miao Mo,Benlong Yang,Qi Zhang,Weiru Chi,Yayun Chi,Jiong Wu.Changing patterns and survival improvements of young breast cancer in China and SEER database, 1999-2017[J].Chinese Journal of Cancer Research,2019,31(4):653-662. 被引量：29

二级参考文献6

1孟祥颖,宋三泰.乳腺癌骨转移药物治疗的疗效评价及分类处理[J].中华肿瘤杂志,2017,39(3):161-165. 被引量：12
2Lei Yang,Rongshou Zheng,Ning Wang,Yannan Yuan,Shuo Liu,Huichao Li,Siwei Zhang,Hongmei Zeng,Wanqing Chen.Incidence and mortality of stomach cancer in China,2014[J].Chinese Journal of Cancer Research,2018,30(3):291-298. 被引量：126
3边莉,徐兵河,邸立军,王涛,王晓稼,焦顺昌,杨俊兰,佟仲生,刘健,冯继锋,刘冬耕,于起涛,刘云鹏,马英,于浩,江泽飞.重组抗HER2人源化单克隆抗体联合长春瑞滨治疗HER2阳性转移性乳腺癌随机对照Ⅲ期临床研究[J].中华医学杂志,2020,100(30):2351-2357. 被引量：28
4Wei Cao,Hong-Da Chen,Yi-Wen Yu,Ni Li,Wan-Qing Chen.Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J].Chinese Medical Journal,2021(7):783-791. 被引量：1343
5国家肿瘤质控中心乳腺癌专家委员会,中国抗癌协会乳腺癌专业委员会,中国抗癌协会肿瘤药物临床研究专业委员会,徐兵河,马飞,樊英,李逸群.中国晚期乳腺癌规范诊疗指南(2022版)[J].中华肿瘤杂志,2022,44(12):1262-1287. 被引量：148
6闫敏,宋三泰,江泽飞,张少华,刘晓晴,徐建明,王涛,罗卫东.乳腺癌骨转移内分泌治疗与化疗的对比研究[J].中华肿瘤杂志,2004,26(3):177-180. 被引量：23

共引文献175

1张良.血清HA水平预测乳腺癌患者改良根治术后淋巴结转移的研究[J].医药论坛杂志,2021,42(14):139-142.
2江莹.正念癌症康复训练对乳腺癌化疗患者心理状态、癌因性疲乏及希望水平的影响[J].反射疗法与康复医学,2022,3(21):165-168.
3Wei Cao,Kang Qin,Feng Li,Wanqing Chen.Socioeconomic inequalities in cancer incidence and mortality:An analysis of GLOBOCAN 2022[J].Chinese Medical Journal,2024,137(12):1407-1413.
4国家肿瘤质控中心乳腺癌专家委员会,马飞,施秀青.乳腺癌骨健康全周期管理规范[J].中华医学杂志,2024,104(2):107-124.
5中国临床肿瘤学会乳腺癌专家委员会,中国抗癌协会乳腺癌专业委员会,中华医学会外科学分会乳腺外科学组,刘强.中国年轻乳腺癌诊疗专家共识(2022)[J].中华医学杂志,2023,103(6):387-403. 被引量：24
6徐新伟,杜秀銮,黄炎,戚显忠,戴丹.年轻乳腺癌患者(<35岁)的临床病理特征及生存预后分析[J].现代实用医学,2020,32(3):327-329. 被引量：5
7徐久成,李成长.具有预后价值的乳腺癌发病关键基因鉴别研究[J].河南师范大学学报（自然科学版）,2020,48(2):27-33.
8马强,熊书,苗加伟,陈洁,周海英,罗娇,杨贞妮,孙厚良,邓雪松.木香烃内酯对人乳腺癌SK-BR-3细胞增殖、迁移和凋亡的影响及机制研究[J].中国药房,2020,31(11):1342-1347. 被引量：4
9Min Yang,Fei Ma,Bo Lan,Jianqiang Cai,Xiaoying Sun,Binghe Xu.Validity of distress thermometer for screening of anxiety and depression in family caregivers of Chinese breast cancer patients receiving postoperative chemotherapy[J].Chinese Journal of Cancer Research,2020,32(4):476-484. 被引量：7
10Li-Xiang Yu,Peng Shi,Xing-Song Tian,Zhi-Gang Yu,无.A multi-center investigation of breast-conserving surgery based on data from the Chinese Society of Breast Surgery(CSBrS-005)[J].Chinese Medical Journal,2020(22):2660-2664. 被引量：17

1邹亚琴.研究团队发现肠道细菌引起女性抑郁症的潜在机制[J].中华医学信息导报,2023,38(6):13-13.
2Jiong Wu,Daiming Fan,Zhimin Shao,Binghe Xu,Guosheng Ren,Zefei Jiang,Yongsheng Wang,Feng Jin,Jin Zhang,Qingyuan Zhang,Fei Ma,Jinli Ma,Zhonghua Wang,Shusen Wang,Xiaojia Wang,Shu Wang,Haibo Wang,Tao Wang,Xiang Wang,Jing Wang,Jia Wang,Biyun Wang,Li Fu,Hongyuan Li,Yehui Shi,Lu Gan,Yunjiang Liu,Jian Liu,Zhenzhen Liu,Qiang Liu,Qiang Sun,Wenwu Cheng,Keda Yu,Zhongsheng Tong,Xinhong Wu,Chuangui Song,Jianguo Zhang,Jian Zhang,Junjie Li,Bin Li,Man Li,Huiping Li,Wentao Yang,Hongjian Yang,Benlong Yang,Hong Bu,Juping Shen,Zhenzhou Shen,Yiding Chen,Ceshi Chen,Da Pang,Zhimin Fan,Ying Zheng,Xiaoli Yu,Guangyu Liu,Xichun Hu,Yiqun Ling,Jinhai Tang,Yongmei Yin,Cuizhi Geng,Peng Yuan,Yajia Gu,Cai Chang,Xuchen Cao,Yuan Sheng,Yuanxi Huang,Jian Huang,Weijun Peng,Xiaohua Zeng,Yuntao Xie,Ning Liao,Committee of Breast Cancer Society,Chinese Anti-Cancer Association.CACA Guidelines for Holistic Integrative Management of Breast Cancer[J].Holistic Integrative Oncology,2022,1(1):76-126. 被引量：2
3肠道菌降解雌二醇导致小鼠抑郁样行为的机制研究[J].微循环学杂志,2023,33(2):37-37.
4杨梅,黄帅,舒茂.MONALEESA-7研究:瑞波西利联合内分泌治疗激素受体阳性绝经前晚期乳腺癌的疗效分析[J].循证医学,2023,23(2):78-82.
5Xue Wang,Jian Yue,Yikun Kang,Zhong Dai,Jie Ju,Jiayu Wang,Pin Zhang,Fei Ma,Binghe Xu,Peng Yuan.Combined chemo-endocrine therapy as a potential new option for HR+/HER2−advanced breast cancer:a prospective study of fulvestrant plus oral vinorelbine[J].Cancer Biology & Medicine,2023,20(4):287-296.
6汪颖,张晓祺.DAWNA-1研究:达尔西利联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效分析[J].循证医学,2023,23(2):83-87. 被引量：1
7代雨婷,张传武.物联网标识原理与方法[J].攀枝花学院学报,2023,40(5):97-104.
8Wei-Yu Bao,Jiang-Hong Zhou,Yan Luo,Yun Lu.Fibromatosis-like metaplastic carcinoma of the breast:Two case reports[J].World Journal of Clinical Cases,2023,11(18):4384-4391.
9申艳,施延生,刘耘,陈洋,孙启蒙,苏琛,王俊杰,鄢友军.超深层复杂岩溶型底水气藏高产稳产主控因素——以安岳气田GS1井区灯二段气藏为例[J].天然气勘探与开发,2023,46(3):59-66.
10郭晓新,李佳慧,张宝亮.基于高分辨率网络的视杯和视盘的联合分割[J].吉林大学学报（工学版）,2023,53(8):2350-2357.

循证医学

2023年第2期

浏览历史

内容加载中请稍等...

瑞波西利联合内分泌治疗用于绝经前侵袭性HR+/HER2-晚期乳腺癌患者:随机Ⅱ期RIGHT Choice试验

参考文献2

二级参考文献6

共引文献175

相关作者

相关机构

相关主题

浏览历史